Objectives There are a number of blockbuster monoclonal antibodies on the market used for the treatment of a variety of diseases. Although the formulation of many antibodies is achieved in 'platform' formulations, some are so difficult to formulate that it can result in an inability to develop a finished drug product. Further, a large number of antibody-inspired or-based molecules are now being developed and assessed for biotherapeutic purposes and less is understood around the required active protein drug concentrations, excipients and additives required in final product formulations. Results We investigated the effect of formulation variables (pH, buffer composition, glycine and NaCl concentration, time and temperature of accelerated stability studies) on antibody solubility/aggregation and activity using a Plackett-Burman Experimental Design approach. We then used the findings from this study and applied these to the formulation of a single chain variable fragment (ScFv) molecule. Our data shows that prediction of ScFc stability from a model monoclonal antibody could be achieved although further formulation optimization was required. Mass spectrometry analysis confirmed changes to the mass and hence authenticity of both the model antibody and ScFv under formulation conditions that did not provide appropriate conditions for protection of the molecules. Conclusions The role of the different formulation conditions on maintaining protein integrity is described and using mass spectrometry shows that protein integrity is compromised under particular conditions. The implications for predicting successful formulations for protein molecules is discussed and how antibody formulations could be used to predict formulation components for novel antibody based molecules.
Introduction
Monoclonal antibody (mAb) based drugs have been a huge success in the clinic and there are many more in development for the treatment of diseases including cancer and rheumatoid arthritis (Ivanov et al. 2009; Ford et al. 2013; Kurata and Nakagawa 2012; Wang et al. 2007; Goi et al. 2014) . Although recombinant proteins can be successfully formulated and stabilised by lyophilisation (Smales et al. 2002; Povey et al. 2009 ), most of the mAb products currently in the clinic are administered by intravenous infusion (Zhu et al. 2014 ). Due to the injection volume that is best for administration (B 1.5 ml), and the large dose requirements for most antibody treatments (C 100-400 mg per treatment), this generally means that antibodies must be formulated as highly concentrated solutions (Dani et al. 2007 ). The development of such high concentration formulations can be challenging due to the increased potential for inter-molecular interactions and macromolecular 'crowding' in solution, and concentration-dependent aggregation (Dani et al. 2007) . Such deleterious effects can lead to issues with stability, activity, pharmacokinetics, potentially patient safety, and practical issues in delivery (Harn et al. 2007) .
The stability of a mAb may be compromised throughout all stages of production and manufacturing by factors including shear, presence of deleterious host cell proteins, pH, buffer composition and temperature. The most common issue associated with instability is aggregation, which is more prominent in high protein concentration solutions (Dani et al. 2007; Demeule et al. 2007a, b; Harn et al. 2007) . Beyond the practical issues of drug delivery, aggregation can also reduce the efficacy of the protein (Cudd et al. 1995) and result in toxic effects and potentially increased immunogenicity (Hermeling et al. 2004) . Aggregates are usually formed after storage at extreme temperatures and pH values that induce protein unfolding and increase the intermolecular interactions of hydrophobic regions which lead to an increase in aggregation events (Carpenter et al. 1999; Liu et al. 2008 ); however at high protein concentrations such events can be observed in the absence of extreme temperature or pH when formulation conditions are unfavourable.
Although many mAb-based drugs have been produced and used as delivery vehicles for other therapeutic molecules, and the formulation of many IgGs is undertaken in platform formulations, there remain cases where it is difficult to successfully formulate particular mAb molecules resulting in an inability to develop a finished drug product. Further, molecules that are constituted of domains or sections of antibody have now also been developed and require different active protein drug concentrations, excipients and additives. Formulation development of recombinant proteins is usually undertaken using a screening approach whereby excipients and additives are changed in order to find a combination that provides the desired stability profile (Almeida et al. 2017; Gourbatsi et al. 2016) . Here, we report on the investigation of the effect of different formulations variables on protein integrity as measured by aggregation, activity, structural and chemical stability using a model mAb IgG4 molecule. We then ask the question as to whether the mAb information could be applied to the design of a formulation of a model single chain Fv (ScFv) molecule. From the findings, we discuss how an understanding of the model mAb and ScFv formulation requirements can be extrapolated to aid in further formulation design of ScFv's.
Materials and methods

Reagents
All reagents were purchased from Sigma-Aldrich and were of analytical grade or higher. The model mAb was an IgG4 lambda molecule that had been produced in Chinese hamster ovary (CHO) cells, purified and formulated in a storage buffer of 50 mM sodium acetate (pH 5.5).
Plackett-Burman design of experiments
The effect of formulation variables (pH, buffer composition, glycine and NaCl concentration, time and temperature of accelerated stability studies) on antibody solubility/aggregation and activity were investigated. In order to investigate the effect of these variables on protein aggregation and stability whilst limiting the potential number of conditions to investigate, a Plackett-Burman experimental design was implemented (Supplementary Tables 1, 2 ) in a manner to that previously described (Gourbatsi et al. 2016) . Triplicate samples were investigated for each formulation and the mean of all analyses calculated. A twotailed t test was used to compare sample means i.e. the low and high values of each variable.
Dialysis, freeze-drying and resuspension of samples in test formulations
In order to remove any existing buffer salts present, protein samples were initially dialysed against the appropriate formulation buffer. The concentration of antibody in solution was monitored before and after storage by measuring the absorbance at 280 nm using a NanoDrop ND-1000 spectrophotometer. After storage under the appropriate conditions, samples were centrifuged at 2009g for 4 min in a benchtop centrifuge. The pellets were carefully separated from the supernatants and resolubilized in 100 ll 8 M urea, 0.25 M Tris/HCl (pH 8.75), 1 mM EDTA. The samples were shaken for several minutes and centrifuged for a further 4 min and then the concentration determined by A 280 measurement. A photographic record of samples before and after storage was also recorded.
SDS-PAGE analysis
Standard SDS-PAGE was undertaken under nonreducing conditions using a 7.5% acrylamide resolving gel and for reduced samples using a 12% acrylamide resolving gel. Samples were adjusted to 1 mg/ml for analysis. The relative quantification of bands was undertaken using the freeware ImageJ software (https://imagej.nih.gov/ij/).
Equilibrium denaturation studies
The stability of the model mAb in high concentration formulations was studied by denaturation analysis using guanidine hydrochloride as the denaturant using the method previously described by Williamson et al. (1994) .
Fluorescence spectroscopy A Cary Eclipse fluorescence spectophotometer (Varian Ltd, Oxford, U.K.) was used. Suspensions of 1 mg/ ml (low protein concentration) and 90 mg/ml (high protein concentrations) were examined. The excitation wavelength was 295 nm and the emission was measured between 300 and 400 nm at 900 V with 10 nm slits. The excitation filter was set to auto and the detector voltage was 900 V. Measurements were taken from an average of four scan passes. For data analysis, the graphs were plotted in Excel and the k max determined. The data was normalized by plotting the ratio of the intensity over maximum wavelength intensity.
Size-exclusion chromatography-HPLC (SEC-HPLC)
The model mAb was analysed on a Waters 600 series HPLC associated with a Waters 486 tunable absorbance detector and absorbance monitored at 220 nm. Samples were diluted to 1 mg/ml and 20 ll injected onto a pre-equilibrated TSK-Gel 3000SWxl column with 0.2 M sodium phosphate buffer pH 7.5. For generation of a standard curve, dilutions of known concentrations of mAb were prepared in 0.2 M sodium phosphate buffer pH 7.5. A constant flow rate (1 ml/min) was used for all runs.
Data analysis
All data was analysed using the Sequential Design of Expert tool (EasyStats, DX7, Version 7.1.6, Stat-Ease Inc., Minneapolis, U.S.A.) to investigate and correlate the effect of individual variables and predict the best formulation conditions for long term storage at 4 and 25°C. The criteria used for selection of the best formulation conditions were to optimize pH, buffer composition, glycine and NaCl concentrations to maximise the concentration of mAb in solution, and the visual appearance to be minimized (0 was scored for a clear solution and 1 was scored for a sample that precipitated), and the k max (fluorescence) to be closest to the standard/control sample.
Heavy and light chain analysis of the model mAb by mass spectrometry Mass spectrometry analysis was undertaken as previously described (Gourbatsi et al. 2016) .
Analysis of a model single chain fragment variable region (ScFv)
A single chain fragment variable region (ScFv) was provided by MedImmune in PBS (pH 7.3). The fragment was dialysed against dH 2 O, freeze-dried and then 0.61 mM samples prepared in appropriate formulations based upon date collected from the model mAb analysis. Samples were analysed as described for the model mAb.
Results
Determination of model mAb solubility with varying formulation
Following standard industrial procedure, an initial impression as to how different formulations affected mAb stability was undertaken visually against an intense light background. Visual analysis indicated that formulations 1, 3, 8 and 12 (Supplementary  Table 2 ) resulted in the majority of mAb precipitating out to form a gel like aggregate (data not shown). The effect of formulation variables on initial protein solubility and any further effect during accelerated storage studies at raised temperature were then investigated by measuring the absorbance at 280 nm immediately after formulation and then again after the relevant storage time (Supplementary Table 1) . Changes in the concentration as determined by A 280 were calculated and the results and statistical analysis are shown in Supplementary Tables 3 and 4 respectively. From the A 280 analysis and two tailed t test statistical testing there was not a single factor identified as being the statistically significant factor impacting upon concentration remaining in solution upon formulation. However, after storage the most significant variable factors were, not surprisingly, protein concentration and the temperature of storage. Of the other variables, although none of these was above the 80% significance level, these generally had more of an effect initially upon formulation than after storage (Supplementary Table 4 ). The data did show, along with the visual data, that several formulations were particularly unsuitable (1, 3, 8, 12) and although all of these were subjected to the high temperature condition, other high temperature formulations were not adversely affected. Of the high protein concentration samples, formulations 4, 9 and 10 did not precipitate compared to high concentration samples 1, 8 and 12. However, formulation 4 was at low temperature for the maximum time investigated, formulation 9 and 10 at low temperature whilst formulations 1 and 12 were stored for the maximum time investigated at maximum temperature and formulation 8 at maximum temperature for 2 h. This suggests that storage temperature was the key variable in the initial study.
SDS-PAGE analysis of MAb samples in the different formulations
SDS-PAGE analysis of all supernatants and pellets of the mAb samples was undertaken in order to investigate changes in protein aggregation (precipitate vs. supernatant) (Fig. 1) . Where it was necessary to resolubilized pellets this was undertaken in 8 M urea (formulations 1, 3, 8, and 12) and for these samples supernatant analysis was not possible. For the mAb sample in formulation 12, not all protein was initially in solution and thus the precipitate observed after storage was not due to the temperature of storage. Differences in the banding pattern in the non-reduced SDS-PAGE gel after storage of formulations 3R (where R stands for resolubilized pellet), 6 and 7 compared to the standard indicates that these formulations and conditions had an impact upon the mAb sample that was not evident from the A 280 measurements alone (Fig. 1a) . Further, upon reduced SDS-PAGE analysis, the samples in formulations 6 and 11 showed a different banding profile from the standard sample (Fig. 1b) .
Determination of soluble aggregates in mAb formulations by size exclusion chromatography (HPLC-SEC)
Quantitative analysis of the amount of soluble aggregate in the different formulated samples was undertaken by size exclusion chromatography and the area under the different peaks representing aggregates of different size determined. Across the samples four major peaks/areas were observed (Fig. 2) . These are labelled as peaks I, II, III and IV in Fig. 2e where peak III corresponds to the fully assembled and intact mAb monomer. Two peaks eluted earlier than the standard corresponding to higher molecular weight aggregates (I and II at 5-6 min and 6-7 min respectively, Fig. 2 ) and one later eluting peak (IV 8-9 min, Fig. 2 ) that was smaller than the monomer and is likely due to disassembled mAb. A summary of the integration of the area under each peak as a percentage of the total area for each sample is depicted in Fig. 3 . The analysis of samples in formulation 2 showed clear evidence of higher molecular weight aggregates as well as disassembled antibody material despite the fact that other methods of analysis had shown no effect of this formulation on stability. Resolubilised material from formulation 8 also revealed the presence of higher order aggregate (Fig. 2) . The amount of each peak in the HPLC-SEC analysis as a percentage of the total peak area is reported in Fig. 2 . In all cases more aggregate or disassembed material was present in the formulated samples after storage than in the standard samples. High molecular weight aggregate was observed after storage of mAb in low protein concentrations and high protein concentration formulations. mAb stability in different formulations as determined by fluorescence and guanidine hydrochloride denaturation studies In order to determine whether any large structural changes were observed in the different mAb high protein concentration formulations, fluorescence studies were undertaken. Figure 4 shows the k max of the mAb samples in the different formulations, an indication of how accessible tryptophan residues are to the solvent. The fluorescence curves show that there was a shift in the observed k max after storage in formulation 12 and smaller shifts after storage in formulations 1, 8 and 4 (Fig. 4a) . A shift to a higher k max is an indication of protein unfolding in these formulations. There was no change in the observed k max for samples in formulation 10 and the fluorescence data for such samples was almost identical to the standard sample (Fig. 4a) . In addition, we undertook guanidine hydrochloride denaturation of the high concentration model mAb that had been stored under different formulation conditions (formulations 4, 9 and 10) to further investigate the conformational stability under the different conditions. The denaturation of the mAb with increasing guanidine hydrochloride concentrations resulted in a small shift in the fluorescence emission maximum when intrinsic fluorescence was excited at 280 nm (Fig. 4b) . The curves all showed one phase of unfolding with the denaturation midpoint occurring at approx. 1.75 M guanidine hydrochloride (Fig. 4b) . All samples will therefore have more-or-less the same DG°(standard free energy change between native and denatured states) and little or no difference in their stability as determined by standard denaturation analysis. Fig. 1 a 7 For mass spectrometry analysis, mAb was initially subjected to reduction and alkylation to allow intact analysis of the heavy and light chains. The major heavy chain (HC) and light chain (LC) masses and relative abundance of each are reported in Fig. 5 . The major HC mass observed in each sample was at approximately 51,171 Da, which corresponds to the expected mass of the mAb heavy chain. A number of other heavy chain species were also present in the standard and formulated samples (Fig. 5a ). Analysis of samples from the different formulations also revealed HC mass peaks not observed in the standard sample, indicative of either loss or gain of mass and therefore protein modification. For example, the HC spectra of samples in formulation 10 contained a peak of mass 47,372 Da, a mass loss of 3797 Da. For the light chain analysis (Fig. 5b) , the major peak observed had a mass of 22,899 Da in the standard sample and a number of higher mass species were also present. As in the case of the heavy chain analyses, samples formulated in formulations 4, 9 or 10 had species of light chain with a different mass to that observed in the control, indicative of protein modification(s) (Fig. 5b) . To determine whether there was any effect on the activity of the model mAb in the high concentration formulations, potency assays were undertaken. Due to the limited amount of antibody in solution after storage in formulations 1, 8 and 12, potency assay measurements were only undertaken after storage in formulations 4, 9 and 10. The resulting dose response curves are shown in Fig. 6 . The data shown reveals that there was no significant change in the activity of the antibody in formulation conditions 4, 9 and 10 compared to the control sample. Thus, under the conditions and formulations of 4, 9 and 10, mAb samples maintained their physical and structural stability and antibody potency/activity.
Statistical analysis of all mAb data
Design-Expert 7.1.6 was used to statistically analyse and correlate the data from all mAb samples and formulations studied here to identify any variable(s) impacting on the stability and integrity of the mAb. Temperature, as expected, was found to be the most important factor of all the responses recorded (solubility, visual appearance, SDS-PAGE analysis, fluorescence, reduced heavy and light chain mass spectrometry analysis and potency of the mAb) after accelerated storage in the appropriate conditions (Table 1) . For some of the responses, the effect of temperature was extremely prominent such as solubility (97.2% increase in protein precipitation as the temperature increases), heavy and light chain mass changes (99.9% change in the mass as the temperature Table shows the reference potency to the mAb STD. There was no significant change in the activity of the mAb after incubation in these formulations although in formulation 4 the potency was slightly elevated and in formulation 10 slightly reduced Biotechnol Lett (2018) 40:33-46 41 increases), aggregation (41.1% change in band intensity as the temperature increases) and potency (43.1% decrease in the activity as the temperature increases) ( Table 1) . Buffer concentration was the next most influential factor affecting the presence of non-covalent aggregates as indicated by structural stability fluorescence analysis (Table 1) . From the data generated, Design Expert was used to predict the formulation condition to be the most appropriate for maintaining the mAb protein integrity at 4 and 25°C and this is reported in Table 2 .
The influence of buffer concentration on a model antibody single chain fragment (ScFv)
The effect of buffer concentration on the stability of an antibody single chain fragment from a variable region (ScFv) was undertaken. The initial formulation used was that based upon the results generated with the model intact mAb and consisted of 250 mM sodium acetate, 0.2 M NaCl and 0.13 M glycine at pH 6.3 and filtered and stored at 4°C and is hence forth referred to as formulation A. Buffer (sodium acetate) at 10, 100, 250 and 500 mM were investigated (with NaCl, glycine and pH kept constant), with ScFV samples formulated in the varying buffer concentrations and the absorbance at 280 nm and fluorescence profiles of the resulting ScFv solutions generated after 1 week of storage at 37°C investigated. The ScFv fragment was soluble in the high buffer concentration formulation (500 mM), but became more insoluble as the buffer concentration was lowered (10 and 100 mM) and in PBS (Table 3) . After a week of storage at 37°C, the 500 mM buffer concentration formulation maintained the ScFv in solution as determined by visual analysis while the remaining buffer concentrations did not appear to deteriorate upon storage any further than observed upon formulation (Table 3) . Despite the small precipitate observed in the PBS, 10 and 250 mM buffer concentration formulations, there were no large apparent structural changes as determined from the fluorescence curves and the k max values (data not shown). Mass spectrometry analysis of the material from the 100, 250 and 500 mM samples revealed no major mass changes compared to the control sample (Fig. 7) . In the resolubilised pellets of the PBS and 10 mM buffer concentration formulations, the most abundant mass peaks upon mass spectrometry analysis were twice the expected mass of the protein. It is likely that dimerization had occurred during storage under these conditions (Fig. 7) . Other mass peaks were also observed that were not in the control sample (Fig. 7) .
Discussion
A potential issue in developing high protein concentration formulations is protein aggregation that Table 3 ScFv visual appearance, precipitation and fluorescence analysis before and after a week of storage at 37°C in 10, 100, 250 and 500 mM buffer concentration formulations (n = 1) Fig. 7 Mass analysis of ScFv samples after incubation in PBS and 100 mM, 250 mM and 500 mM buffer concentration formulations (Res resolubilized pellet). The figure shows the abundance of each peak as a percentage of the most abundant peak which was assigned a value of 100%
compromises quality control and biological activity, whilst the administration of such aggregates can lead to immune-related adverse effects (Harn et al. 2007; Shire et al. 2004; Kameoka et al. 2007) . The effect of different formulations variables including protein concentration, pH, buffer composition, time of storage, storage, temperature, glycine and salt (NaCl) concentration was therefore investigated on a model mAb. Visual analysis showed that the antibody precipitated out of solution after storage in formulations 1, 8 and 12 with the most significant factor in terms of accelerating aggregation, unsurprisingly, being temperature. The impact of temperature in promoting aggregation events for monoclonal antibodies (and proteins in general) has been well documented (e.g. Cleland et al. 2001; Chen et al. 2003; Breen et al. 2001) . At elevated temperatures, proteins can partial/completely unfold and for this reason storage temperature is set well below the thermal melting for long term stability at 2-8°C (Perico et al. 2008) . However, temperature is used during formulation studies to accelerate stability studies and identity formulations that are less stable, or in this case formulation components. The protein concentrations in solution were determined in the different formulations spectrophotometrically at 280 nm before and after storage and statistical analysis was then applied to the results to identify the variables in terms of aggregation that appeared most significant. This analysis showed that protein concentration and temperature of storage were statistically significant with respect to changes in protein concentration. Much work has been undertaken into this area, for example a study by Perico et al. using an IgG2 monoclonal antibody demonstrated that the aggregation of this antibody was temperature dependent. This finding agrees with the analysis here where temperature positively impacted upon the precipitation of mAb. In particular, under storage conditions of 2-8°C at pH 4.0 there was minimal aggregation while at elevated temperatures (37°C) the acidic formulations lead to the presence and detection of high order aggregates. Ejima et al. did not detect a significant increase in aggregation of a recombinant humanized IgG4 after storage at pH 2.7 and 3.5 at 4°C (Ejima et al. 2007) in agreement with the data presented here where after storage in formulation 4 at pH 4.0 and 4°C there was no evidence of aggregation based on the A 280 measurements, SDS-PAGE or SEC-HPLC analysis. Thus, low pH alone was not enough to destabilize the antibody. On the other hand, after storage in formulation 8 at pH 4.0 at elevated temperature (55°C) there was a significant increase in aggregation events. This agrees with others who have reported the formation of aggregates of a chimeric monoclonal antibody at pH values below 5 at 60°C (Paborji et al. 1994) . However, Kuetzo et al. reported an increase in aggregation at decreased pH of an IgG2 monoclonal antibody during freeze-thawing after storage at 4°C for up to 6 weeks, and moreover, that the aggregation was most prevalent at pH 3 and 4 (Kueltzo et al. 2008) . This contrasts with the data presented here where formulation 4 is very similar to those in the report by Kuetzo et al. but minimal aggregation of the MAb in this formulation was observed. In a further study two mouse monoclonal antibodies were stored at 37°C, pH 3 and pH 4, and at 4°C, pH 3.0 and insoluble aggregates were observed (Jiskoot et al. 1990 ). All of these studies demonstrate the importance of temperature in the formation of aggregates, especially at low pH, but importantly the different behaviour of different antibodies and the fact this can be prevented by manipulating formulation conditions.
The presence of non-covalent and covalent aggregates in solution was investigated by reduced and nonreduced SDS-PAGE. Unfortunately, analysis of the aggregates in high concentration formulations where changes were observed in solution was difficult due to the amount of aggregation. As a result, the precipitate was resolubilized with 8 M Urea/Tris/EDTA, but this can disrupt the aggregates present and give misleading results. This method was successful for analysis of formulation 8 where less precipitate was observed and in the subsequent SEC analysis high molecular weight aggregates were observed. Surprisingly, in the low mAb concentration formulation 2, the same high molecular weight aggregates were observed and a smaller molecular weight peak that corresponds to disassembled antibody. The temperature of storage in this formulation was high (55°C) and this might explain the formation of aggregates. These data show that even in a clear solution aggregates can be present. Long term storage of such samples could result in the early aggregate material leading to further aggregates or fibril formation and gelation with time as has been previously described (Demeule et al. 2007a, b) .
Protein aggregation usually involves structural and conformational changes to the protein (Demeule et al. 2007a, b) . The structural integrity of the model mAb here after storage in high concentration formulations was therefore investigated by fluorescence analysis. The k max curves revealed that the mAb in majority of high concentration formulations remained folded although in formulations 1, 8 and 12 that had high storage temperature (55°C) there was a shift in k max to higher values indicating structural change and unfolding. This red shift indicates that there are local changes in the environment of tryptophan, tyrosine and phenylalanine residues and suggests that there may be a decrease in the hydrophobicity around these residues i.e. local environment around tryptophan molecules is more hydrophilic.
The conformational stability of the model mAb after storage in different formulations was also investigated by guanidine hydrochloride denaturation studies. The change in the k max was used to follow the denaturation of the protein with increasing guanidine concentrations (Williamson et al., 1994) . Due to limitations in amount of sample, the analysis was only carried out for the high concentration formulations 4, 9 and 10. Previous analysis of these formulations showed no or minimal evidence of aggregation and a single-state unfolding was observed for the denaturation curves. Little difference in the concentration of guanidine required to initiate and complete the unfolding between samples in the different formulations was observed, suggesting that tertiary structure stability was more-or-less the same in all samples investigated. The potency of these samples was also investigated and statistical analysis suggested there was a significant difference in the potency of the material from these formulations.
There are now a number of different antibody formats on the market and in development, including single chain fragments from variable regions (ScFv, * 20-30 Da). These smaller molecules can also have stability issues, particularly due to the absence of sections of the constant region of the light or heavy chain resulting in the exposure of hydrophobic side chains (Worn and Pluckthun 1999; Barthelemy et al. 2008) . Therefore, we investigated the impact of buffer concentration and composition, as in the case of the model mAb, on a model ScFv. In contrast to the full length mAb, the fragment did not easily go into solution at 10 mM buffer concentration or in PBS and after 1 week of storage at 37°C there was much insoluble material present. The best buffer concentration formulation for solubility of the ScFv of those investigated was that at a concentration of 500 mM, where the fragment went easily into solution and remained so after the appropriate storage. A possible explanation might be that at this concentration the fragment had reached its isotonicity (where the solute, in this case the ScFv, concentration is the same as the concentration of the solution surrounding it). Changes in the overall charge of the fragment that could result in an increase/decrease of the hydrophobicity might be another factor. Regardless, the work here demonstrates that potency may not necessarily be impacted by modifications (as determined by mass spectrometry) of a model mAb and that despite the large amount of work undertaken to further our understanding of how formulation conditions can impact upon mAb and general protein stability, the use of 'platform' formulation been adopted across the industry, it is still necessary to screen excipients and formulations to identify appropriate formulations for biotherapeutics and prediction of formulation performance remains a challenging area.
